Hyderabad, Telangana, India, January 2025 – Dr. Vellaian Karuppiah has been appointed as the Chief Operating Officer for Acme and the Immacule Group of Companies, bringing over three decades of expertise in pharmaceutical operations. In his new role, Dr. Karuppiah will focus on enhancing process optimization and strengthening sterile and oral solid dosage formulation operations through his strategic leadership and technical excellence.
Prior to his current role, Dr. Vellaian Karuppiah served as Head of Operations at Gland Pharma Limited for approximately 2 years, where he led the overall operations strategy and performance improvement initiatives in pharmaceutical manufacturing.
Before Gland Pharma, he was the Global Head – Manufacturing Science & Technology (MS&T) and Operations at Strides Pharma Science Limited for around 2 years, where he was responsible for process development, technology transfer, site transfer projects, and ensuring successful new product launches across multiple global manufacturing sites.
Dr. Karuppiah spent approximately 8 years at Dr. Reddy’s Laboratories, where he held various senior leadership positions, including Head of Process Development and Tech Operations, Delivery Head of Topical Formulations and Operations, and Site Head and Cluster Operations. His contributions included driving process standardization, CMC project management, and packaging development.
Earlier in his career, he held key leadership roles at Actavis (now Teva) as General Manager and Head of Process Development & Technology Transfer, focusing on ANDA and EU dossier filings, scale-up, and process validation for global markets. He also worked at Wockhardt Ltd. and Orchid Healthcare, where he led global technical services, process validation, and technology transfer projects for a diverse range of pharmaceutical products.
About Acme Generics:
Acme Generics is a prominent provider of Oral Solid and Sterile Dosage Form contract manufacturing and development services for the pharmaceutical industry. Established in 2005, the company has grown into a trusted CDMO partner with expertise in hormonal formulations, general injectables, and lyophilized products. Acme operates three state-of-the-art manufacturing facilities in Northern India with a total capacity of 15 billion tablets, 5 billion capsules, and 42 million ampoules/vials. The company’s commitment to quality and global standards has earned it approvals from USFDA, UKMHRA, EU-GMP, and several other international regulatory bodies.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
